4.6 Editorial Material

Does an Intradermal Vaccination for Monkeypox Make Sense?

期刊

AAPS JOURNAL
卷 24, 期 6, 页码 -

出版社

SPRINGER
DOI: 10.1208/s12248-022-00754-6

关键词

FDA guidance; Intradermal; Monkeypox; Vaccination

向作者/读者索取更多资源

Mankind has recently faced a series of virus-mediated pandemics, causing significant strain on healthcare systems. The highly mobile nature of our society has posed challenges in limiting the spread of highly transmissible viruses before the availability of vaccines. The global efforts to address the recent SARS-CoV-2 pandemic have highlighted the strengths and weaknesses of vaccine identification, testing, and use. The lack of clear and consistent messaging, due to the compressed timeline of research and development, has further complicated the situation.
Mankind has recently had to deal a series of virus-mediated pandemics, resulting in extensive morbidity and mortality rates that have severely strained healthcare systems. While dealing with viral infections as a healthcare concern is not new, our exceptionally mobile society has added to the critical challenge of limiting pathogen spread of a highly transmissible virus prior to the generation, testing, and distribution of safe and effective vaccines. The tremendous global effort put forth to address the recent pandemic induced by SARS-CoV-2 infection has highlighted many of the strengths and weaknesses of how vaccines are identified, tested, and used to provide protection. These uncertainties are exacerbated by the lack of clear and consistent messaging that can occur when the processes of research, development, and clinical testing that normally requires years of study and consideration are compressed into a few months. In this commentary, I will provide some background on the intramuscular (IM), subcutaneous (SC), and intradermal (ID) administration routes used for injectable vaccines and some information on potential immunological outcomes. With this background, I will address the recent FDA decision to allow an approved vaccine against monkeypox virus to be administered by ID, as well as its initial approval route via SC, injection as a dose-sparing strategy to maximize immunization numbers using current stockpiles.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据